Wockhardt to Exit US Generic Business, Shifts Focus to Antibiotics and Diabetes Care
Strategic Realignment Aims at Innovation-Driven Growth
Pharmaceutical company Wockhardt announced on Friday that it will exit its loss-making US generic drug business as part of a strategic overhaul, shifting its focus toward high-growth areas such as antibiotics and biologics for diabetes care.

The Mumbai-based firm stated that the move is aligned with its long-term vision to transform into a differentiated and innovation-led pharmaceutical company. The decision marks a significant pivot from the highly competitive and price-sensitive US generics market to a more research-oriented business model.

“In line with our strategic roadmap, we are realigning our US business to focus on new drug discovery and specialty products in antibiotics and diabetes care,” the company said in an official statement.

Wockhardt emphasized that its new focus areas will include advanced antibiotics, an area in which the company already has a strong legacy, as well as biological drugs targeting diabetes—one of the fastest-growing therapeutic segments globally.

The company did not provide specific timelines for the phase-out of its US generics operations but noted that it would continue to meet regulatory obligations and contractual commitments during the transition period.

Analysts believe that this move will allow Wockhardt to free up resources and invest in high-margin, research-intensive areas that align with global healthcare needs and future demand.

The exit comes amid ongoing challenges faced by Indian pharmaceutical firms in the US generics market, including price erosion, intense competition, and regulatory hurdles. By narrowing its focus, Wockhardt aims to rebuild a sustainable and innovation-driven business model.

The company said it will share further updates on its new product pipeline and investment plans in the coming quarters.